OR WAIT null SECS
January 03, 2019
Merger cites combined strengths in oncology, immunology and inflammation, and cardiovascular disease.
January 02, 2019
Orphan and cancer drugs continue to lead, but treatments for many common diseases were also approved in 2018.
Pricing pressures, investment volatility, and government disfunction greet Pharma in 2019.
While pharma is proving its capabilities to develop novel therapies, the industry still needs to work on manufacturing innovation.
Keeping valuable employees happy-and on the job-may test bio/pharma business decisions.
As Brexit rapidly approaches, the lack of clarity around the regulatory balance between the regions could lead to a reduction in standards.
January 01, 2019
Intellectual challenge, work/life balance, compensation, and an unclear business outlook create uncertainty among European bio/pharma employees.
December 19, 2018
The proposed $12.7-billion deal includes the spinoff of GSK and Pfizer consumer brands to a new UK-listed company.
December 02, 2018
Taking stock on the ‘big-ticket’ news items, both good and bad, from the past 12 months.
November 30, 2018
The acquisition will give Genentech full rights to Jecure’s preclinical portfolio of NLRP3 inhibitors.